A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
|Articles|October 5, 2012
VIDEO: Aimee Tharaldson, PharmD, Discusses the Impact of Biosimilars on the Specialty Pharmacy Market
In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics Express Scripts, Inc, talks about the impact that biosimilar medications could potentially have on the specialty pharmacy market.
Advertisement
In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics Express Scripts, Inc, talks about the impact that biosimilar medications could potentially have on the specialty pharmacy market.
Although Dr. Tharaldson says that there has not been an impact yet, she says that "eventually, once more guidance is available, we will see more of the true biosimilars approved. Once we can get these to be interchangable at the point of service -- that's where we're going to see a lot of cost savings."
This video was taken on Thursday, October 4, 2012, at the Academy of Managed Care Pharmacy's 2012 Educational Conference in Cincinnati, OH.
Advertisement
Related to this article
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5